An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Completed · Phase 1/Phase 2

Conditions studied: Non-Hodgkin's Disease

In brief

The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Primary Mediastinal Large B-Cell Lymphoma (PMBL) and Mediastinal Gray Zone Lymphoma (MGZL).

Key facts

Study ID

NCT02581631

Run by

Bristol-Myers Squibb

People needed

145

Starts

2016-02-11

Expected to finish

2022-02-07

Last updated by the study team

2023-03-07

Who can join

Age: 15 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed/refractory diffuse large B cell lymphoma (DLBCL), relapsed/refractory peripheral T cell lymphoma (PTCL) (all subtypes excluding anaplastic large cell lymphoma), relapsed/refractory Cutaneous T cell lymphoma (CTCL) mycosis fungoides/sezary syndrome (MF/SS), relapsed/refractory primary mediastinal B lymphoma (PMBL), and relapsed/refractory mediastinal gray zone lymphoma (MGZL)
• Expression of CD30
• Subjects must be 18 years or older (≥ 15 years for PMBL)

You may not qualify if…

• Known central nervous system (CNS) lymphomas; Active cerebral/meningeal disease related to the underlying malignancy
• Active, known, or suspected autoimmune disease

Where it is running

• Local Institution - 0017 — Birmingham, Alabama, United States
• University Of Miami Sylvester Comprehensive Cancer Center — Miami, Florida, United States
• Local Institution - 0012 — Tampa, Florida, United States
• Winship Cancer Institute. — Atlanta, Georgia, United States
• University Of Chicago — Chicago, Illinois, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Washington University School Of Medicine — St Louis, Missouri, United States
• Local Institution - 0003 — New York, New York, United States
• Local Institution - 0010 — New York, New York, United States
• University Of Rochester — Rochester, New York, United States
• Levine Cancer Institute — Charlotte, North Carolina, United States
• The Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
• Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
• Providence Portland Medical Center — Portland, Oregon, United States
• Bon Secours-St Francis Hosp — Greenville, South Carolina, United States
• University of Washington - Seattle Cancer Care Alliance — Seattle, Washington, United States
• BC Cancer Agency - Vancouver Centre — Vancouver, British Columbia, Canada
• Local Institution - 0011 — Toronto, Ontario, Canada
• Jewish General Hospital — Montreal, Quebec, Canada
• Hopital Saint Louis — Paris, France
• Local Institution - 0020 — Pierre-Bénite, France
• Local Institution - 0018 — Bergamo, Italy
• Local Institution - 0024 — Bologna, Italy
• Istituto Clinico Humanitas — Rozzano (milano), Italy
• Local Institution - 0027 — Hospitalet de Llobregat - Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.